Improvement in cognitive function following a switch to ziprasidone from conventional antipsychotics, olanzapine, or risperidone in outpatients with schizophrenia

被引:80
作者
Harvey, PD
Meltzer, H
Simpson, GM
Potkin, SG
Loebel, A
Siu, C
Romano, SJ
机构
[1] CUNY, Mt Sinai Med Ctr, New York, NY 10029 USA
[2] Hosp Psychiat, Vanderbilt Med Ctr, Nashville, TN 37212 USA
[3] Univ So Calif, LAC Med Ctr, Dept Psychiat, Los Angeles, CA USA
[4] Univ Calif Irvine, Neuropsychiat Ctr, Irvine, CA 92868 USA
[5] Pfizer Inc, Pfizer Pharmaceut Grp, New York, NY 10017 USA
关键词
schizophrenia; cognition; ziprasidone; atypical antipsychotics; executive functioning; vigilance; attention; verbal fluency;
D O I
10.1016/j.schres.2003.07.009
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Objective: To assess changes in cognitive function in stable outpatients with schizophrenia switched to ziprasidone from conventional antipsychotics (n = 108), olanzapine (n = 104), or risperidone (n = 58) because of suboptimal efficacy or poor tolerability. Methods: In three separate 6-week trials, patients received ziprasidone 40 mg b.i.d. for 2 days, followed by 20-80 mg b.i.d. for the next 40 days. Before switching, and at endpoint, patients were evaluated with tests of working and secondary verbal memory, vigilance, visuomotor speed, verbal fluency, and executive functioning. Principal components factor analysis was performed to test for clustering of cognitive variables. Results: Significant improvements were seen at endpoint in secondary verbal memory (in all three groups), vigilance (in patients switched from conventional antipsychotics or risperidone), executive function (in patients switched from conventional antipsychotics or risperidone), and verbal fluency. Factor analysis on baseline scores suggested reduction of the cognitive variables to three factors: verbal skills, attention and short-term memory, and executive functioning. Analysis of z-transfonned mean change in factor scores showed significant improvement in verbal skills and global score following the switch from conventional antipsychotics, olanzapine, or risperidone. Conclusions: Patients requiring a change in antipsychotic therapy may exhibit cognitive improvement following a switch to ziprasidone. (C) 2003 Elsevier B.V. All rights reserved.
引用
收藏
页码:101 / 113
页数:13
相关论文
共 46 条
[11]  
GELENBERG AJ, 1989, J CLIN PSYCHOPHARM, V9, P180
[12]   An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder [J].
Goff, DC ;
Posever, T ;
Herz, L ;
Simmons, J ;
Kletti, N ;
Lapierre, K ;
Wilner, KD ;
Law, CG ;
Ko, GN .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 1998, 18 (04) :296-304
[13]  
Green MF, 1997, AM J PSYCHIAT, V154, P799
[14]   Neurocognitive deficits and functional outcome in schizophrenia: Are we measuring the "right stuff"? [J].
Green, MF ;
Kern, RS ;
Braff, DL ;
Mintz, J .
SCHIZOPHRENIA BULLETIN, 2000, 26 (01) :119-136
[15]  
Green MF, 1996, AM J PSYCHIAT, V153, P321
[16]   IMPROVEMENT IN COGNITIVE FUNCTIONS AND PSYCHIATRIC-SYMPTOMS IN TREATMENT-REFRACTORY SCHIZOPHRENIC-PATIENTS RECEIVING CLOZAPINE [J].
HAGGER, C ;
BUCKLEY, P ;
KENNY, JT ;
FRIEDMAN, L ;
UBOGY, D ;
MELTZER, HY .
BIOLOGICAL PSYCHIATRY, 1993, 34 (10) :702-712
[17]   Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment [J].
Harvey, PD ;
Keefe, RSE .
AMERICAN JOURNAL OF PSYCHIATRY, 2001, 158 (02) :176-184
[18]  
Harvey PD, 2002, J CLIN PSYCHIAT, V63, P1065
[19]  
HARVEY PD, 2003, IN PRESS PSYCHOPHARM
[20]  
Heaton R.K., 1981, MANUAL WISCONSIN CAR